SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(AMENDMENT NO. 2 ) 1
-----
Senesco Technologies, Inc.
--------------------------
(Name of Issuer)
Common Stock, $.01 par value
------------------------------
(Title of Class of Securities)
817208 40 8
--------------
(CUSIP Number)
Joel Brooks, 303 George Street, Suite 420, New Brunswick, New Jersey 08901
- --------------------------------------------------------------------------------
(732-296-8400)
--------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
December 31, 2001
-----------------
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box. |_|
Note. Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits.
See Rule 13d-7(b) for other parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 6 Pages)
- ----------------------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
- ------------------------------- ---------------------------------
CUSIP No. 817208 40 8 13D Page 2 of 6 Pages
------------ --- ---
- ------------------------------- ---------------------------------
- -----------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
John E. Thompson, Ph.D.
------------------------
- -----------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)|_|
(b)|_|
- -----------------------------------------------------------------------------
3 SEC USE ONLY
- -----------------------------------------------------------------------------
4 SOURCE OF FUNDS * PF
- -----------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2 (e) |_|
- -----------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Canada
--------------
- -----------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 638,667
----------
SHARES ------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER N/A
OWNED BY ------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER 638,667
---------
REPORTING ------------------------------------------------------------
PERSON WITH 10 SHARED DISPOSITIVE POWER N/A
- -----------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
638,667
---------
- -----------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* |_|
- -----------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 6.35%
---------
- -----------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON* IN
- -----------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
ITEM 1. SECURITY AND ISSUER.
The title of the class of equity securities to which this statement
relates is common stock, $.01 par value (the "Common Stock"), of
Senesco Technologies, Inc., a Delaware corporation (the "Company").
The address of the principal executive offices of the Company is 303
George Street, Suite 420, New Brunswick, New Jersey 08901.
ITEM 2. IDENTITY AND BACKGROUND.
(a) The name of the person filing this statement is John E. Thompson,
Ph.D.;
(b) The business address of Dr. Thompson is c/o Senesco Technologies,
Inc., 303 George Street, Suite 420, New Brunswick, New Jersey
08901;
(c) The present principal occupation or employment of Dr. Thompson is
Executive Vice- President of Research and Development of the
Company;
(d) During the last five years, Dr. Thompson has not been convicted
in a criminal proceeding (excluding traffic violations or similar
misdemeanors);
(e) During the last five years, Dr. Thompson was not a party to a
civil proceeding of a judicial or administrative body of
competent jurisdiction as a result of which proceeding it was or
is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to,
federal or state securities laws or finding any violation with
respect to such laws; and
(f) Dr. Thompson is a citizen of Canada.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
On October 9, 1998, Senesco, Inc., a New Jersey corporation
("Senesco"), Nava Leisure USA, Inc., an Idaho corporation ("Nava"),
Nava Leisure Acquisition Corp., a New Jersey corporation and
wholly-owned subsidiary of Nava ("NAC"), and the Principal
Stockholders (as defined therein), entered into an Agreement and Plan
of Merger, providing for the merger of NAC with and into Senesco, and
the issuance to the shareholders of Senesco one newly issued share of
Common Stock of Nava for each share of Common Stock of Senesco whereby
the shareholders of Senesco acquired a majority of the issued and
outstanding shares of Common Stock of Nava (the "Merger"). The Merger
was consummated on January 22, 1999, the date upon which the
Certificate of Merger filed with the Secretary of State of the State
of New Jersey was declared effective. Upon the consummation of the
Merger, Senesco was the surviving corporation and remained a
subsidiary of Nava which changed its name to Senesco Technologies,
Inc., an Idaho corporation ("STI").
Dr. Thompson was a shareholder of Senesco and beneficially owned
425,000 shares of Common Stock of Senesco. As a result of the Merger,
on January 22, 1999, Dr. Thompson received 425,000 shares of Common
Stock of STI (formerly Nava), consisting of 15.74% of the 2,700,008
shares of STI Common Stock issued and outstanding.
On September 7, 1999, STI granted to Dr. Thompson options to purchase
40,000 shares of STI Common Stock, on a post stock split adjusted
basis (as described below), at an exercise price equal to $3.85 per
share. Dr. Thompson received such options as consideration for his
services as an executive officer of STI. All such options are
currently vested.
On September 29, 1999, STI declared a two-for-one forward stock split
of its issued and outstanding Common Stock and, as a result, Dr.
Thompson's holdings of STI Common Stock increased to 850,000 shares,
excluding any options to purchase shares of STI Common Stock.
On September 30, 1999, STI merged with and into the Company, for the
sole purpose of reincorporating the corporation from the State of
Idaho to the State of Delaware.
Page 3 of 6 Pages
ITEM 4. PURPOSE OF TRANSACTION.
Dr. Thompson acquired the 850,000 shares of the Company's Common
Stock, on a post stock split adjusted basis, as a result of the Merger
as discussed in Item 3 above.
On December 1, 2001, the Company granted to Dr. Thompson options to
purchase 80,000 shares of the Company's Common Stock at an exercise
price equal to $2.05 per share, pursuant to the Company's 1998 Stock
Incentive Plan, as amended. Dr. Thompson received such options as
consideration for his services as an executive officer of the Company.
One-third (1/3) of such options became exercisable on the date of
grant, one-third (1/3) of such options shall become exercisable on
December 1, 2002, and one-third (1/3) of such options shall become
exercisable on December 1, 2003.
On December 10, 2001, Dr. Thompson sold 250,000 shares of the
Company's Common Stock to an unrelated third party pursuant to a
private resale agreement.
On December 18, 2001, Dr. Thompson gifted 28,000 shares of the
Company's Common Stock for no consideration to the University of
Waterloo, an educational institution in which neither he nor any
member of his family exercises investment control or possesses voting
or dispositive power.
Dr. Thompson may from time to time, depending upon market conditions,
the state of affairs of the Company and other factors, acquire
additional shares of Common Stock of the Company, subject to
applicable laws and to the availability of shares at prices deemed
favorable. Alternatively, Dr. Thompson may dispose of shares of the
Company's Common Stock. Dr. Thompson will continue to consider his
equity interests in the Company and he reserves the right to formulate
such plans or proposals, and to take such action, as he may deem
appropriate in light of future circumstances.
Except as set forth above, Dr. Thompson does not have any present
plans or intentions which would result in or relate to any of the
following:
(a) The acquisition by any person of additional securities of the
Company, or the disposition of securities of the Company;
(b) An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Company;
(c) A sale or transfer of a material amount of assets of the Company;
(d) Any change in the present board of directors or management of the
Company, including any plans or proposals to change the number or
terms of directors or to fill any existing vacancies on the
board;
(e) Any material change in the present capitalization or dividend
policy of the Company;
(f) Any other material change in the Company's business or corporate
structure;
(g) Changes in the Company's charter, bylaws or instruments
corresponding thereto or other actions which may impede the
acquisition of control of the Company by any person;
(h) Causing a class of securities of the Company to be delisted from
a national securities exchange or to cease to be authorized to be
quoted in an inter-dealer quotation system of a registered
national securities association;
(i) A class of equity securities of the Company becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the
Act; or
(j) Any action similar to any of those enumerated above.
Page 4 of 6 Pages
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) Dr. Thompson beneficially owns 638,667 shares of the Company's
Common Stock, including options to purchase 66,667 shares of
Common Stock exercisable within 60 days. Dr. Thompson's 638,667
shares of Common Stock represents 6.35% of the issued and
outstanding shares of the Company's Common Stock, based on
9,987,187 shares issued and outstanding as of December 31, 2001.
(b) Dr. Thompson has the sole power to vote or to direct the vote of
all of the 638,667 shares of the Company's Common Stock, assuming
the exercise of all options.
(c) On September 7, 1999, the Company granted to Dr. Thompson options
to purchase 40,000 shares of the Company's Common Stock, at an
exercise price equal to $3.85 per share. One-half (1/2) of such
options vested on the date of grant and one-half (1/2) of such
options vested on June 30, 2000. Such options were issued to Dr.
Thompson in consideration for his services as an executive
officer of the Company.
On December 1, 2001, the Company granted to Dr. Thompson options
to purchase 80,000 shares of the Company's Common Stock at an
exercise price equal to $2.05 per share, pursuant to the
Company's 1998 Stock Incentive Plan, as amended. One-third (1/3)
of such options vested on the date of grant, one-third (1/3) of
such options shall become vested on December 1, 2002, and
one-third (1/3) of such options shall become vested on December
1, 2003. Such options were issued to Dr. Thompson in
consideration for his services as an executive officer of the
Company.
In 2001, the percentage of the issued and outstanding Common
Stock of the Company beneficially owned by Dr. Thompson was
materially reduced due to (i) his sale of 250,000 shares of the
Company's Common Stock to an unrelated third party, and (ii) the
Company's private placements of 1,142,858 and 665,714 shares of
its restricted Common Stock, completed in December 2001.
(d) No other person is known to have the right to receive or the
power to direct the receipt of dividends from, or the proceeds
from the sale of, such securities.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH THE
ISSUER.
There is no contract, arrangement, understanding or relationship
(legal or otherwise) between Dr. Thompson and the Company with respect
to any securities of the Company, including but not limited to,
transfer of voting of any of the securities, finder's fees, joint
ventures, loan or option arrangements, puts or calls, guarantees of
profits, division of profits or loss, or the giving or withholding of
proxies.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
None.
Page 5 of 6 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 13, 2002 /s/ John E. Thompson
------------------------------------------
John E. Thompson, Ph.D., Stockholder
The original statement shall be signed by each person on whose behalf
the statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention. Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
Page 6 of 6 Pages